scholarly journals Mesenchymal stromal cell potency to treat acute kidney injury increased by ultrasound-activated interferon-γ/interleukin-10 axis

2018 ◽  
Vol 22 (12) ◽  
pp. 6015-6025 ◽  
Author(s):  
Scott R. Burks ◽  
Matthew E. Nagle ◽  
Michele N. Bresler ◽  
Saejeong J. Kim ◽  
Robert A. Star ◽  
...  
Cytotherapy ◽  
2019 ◽  
Vol 21 (5) ◽  
pp. e5
Author(s):  
R. Barcia ◽  
A. Allen ◽  
N. Vaninov ◽  
S. Nguyen ◽  
L. Goodale ◽  
...  

Stem Cells ◽  
2015 ◽  
Vol 33 (4) ◽  
pp. 1241-1253 ◽  
Author(s):  
Scott R. Burks ◽  
Ben A. Nguyen ◽  
Pamela A. Tebebi ◽  
Saejeong J. Kim ◽  
Michele N. Bresler ◽  
...  

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S20
Author(s):  
J. Teixiera ◽  
M.G. Atta ◽  
L. Noureddine ◽  
S. Nguyen ◽  
B. O’Rourke ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Mujib Ullah ◽  
Daniel D. Liu ◽  
Sravanthi Rai ◽  
Mehdi Razavi ◽  
Waldo Concepcion ◽  
...  

Abstract Background Acute kidney injury (AKI) is characterized by rapid failure of renal function and has no curative therapies. Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) are known to carry therapeutic factors, which have shown promise in regenerative medicine applications, including AKI. However, there remains an unmet need to optimize their therapeutic effect. One potential avenue of optimization lies in pulsed focused ultrasound (pFUS), where tissues-of-interest are treated with sound waves. pFUS has been shown to enhance MSC therapy via increased cell homing, but its effects on cell-free EV therapy remain largely unexplored. Methods We combine pFUS pretreatment of the kidney with MSC-derived EV therapy in a mouse model of cisplatin-induced AKI. Results EVs significantly improved kidney function, reduced injury markers, mediated increased proliferation, and reduced inflammation and apoptosis. While pFUS did not enhance EV homing to the kidney, the combined treatment resulted in a superior therapeutic effect compared to either treatment alone. We identified several molecular mechanisms underlying this synergistic therapeutic effect, including upregulation of proliferative signaling (MAPK/ERK, PI3K/Akt) and regenerative pathways (eNOS, SIRT3), as well as suppression of inflammation. Conclusion Taken together, pFUS may be a strategy for enhancing the therapeutic efficacy of MSC-derived EV treatment for the treatment of AKI.


2019 ◽  
Vol 13 (1) ◽  
pp. 3-14
Author(s):  
Federica Casiraghi ◽  
Giuseppe Remuzzi

Intense investigation in pre-clinical models of kidney disease and transplantation showed that mesenchymal stromal cell (MSC) therapy acts on renal and inflammatory cells in multiple, complex and integrated ways, resulting in cell repair and regeneration, in the inhibition of inflammatory cells, and in the development of cells endowed with their own anti-inflammatory and immuneregulatory properties. These encouraging data paved the way for exploring the use of MSC in clinics as innovative therapeutic tools for patients with renal diseases and transplantation. In this review, we describe the available results of clinical studies of MSC in patients with post-cardiac surgery, acute kidney injury, chronic kidney diseases - including diabetes, renovascular disease and lupus nephritis - and in kidney transplant recipients, with a particular focus on our experience with MSC therapy as a pro-tolerogenic strategy in kidney transplantation. The available studies, mainly phase 1, indicated that MSC therapy is safe and feasible and not associated with adverse events, at least in the short- and mid-term. Encouraging results have been reported in renovascular disease and kidney transplantation, while studies in acute kidney injury and chronic kidney disease had contrasting outcomes. The relevant issues and the knowledge gap that still limit the translation of MSC cell therapy into clinical practice are discussed briefly.


Molecules ◽  
2019 ◽  
Vol 25 (1) ◽  
pp. 15 ◽  
Author(s):  
Beibei Zhang ◽  
Mengnan Zeng ◽  
Meng Li ◽  
Yuxuan Kan ◽  
Benke Li ◽  
...  

Corydalis humosa Migo is a traditional Chinese medicine that clears away damp heat, relieves sore. Protopine (PRO) is an alkaloid component isolated from C. humosa Migo. However, the role of protopine in acute kidney injury (AKI) has not yet been reported. This study aims to investigate the effect and mechanism of protopine isolated from C. humosa Migo on lipopolysaccharide (LPS)-induced AKI in mice. Inflammation accumulation was assessed by small animal living imaging. The blood urea nitrogen (BUN), and serum creatinine (Scr) were measured to assess the effects of protopine on renal function in LPS-induced AKI. The levels of tumor necrosis factor (TNF), interleukin-2 (IL-2), interferon-γ (IFN-γ), and (interleukin-10) IL-10 in serum were detected by cytometric bead array. Flow cytometry was used to detect the levels of reactive oxygen species (ROS) in primary kidney cells. The proportions of granulocytes, neutrophils, and macrophages in peripheral blood were examined to evaluate the effect of protopine on immune cells in mice with AKI. Toll-like receptor (TLR4) and apoptotic signaling pathway were detected by Western blot analysis. The results showed that protopine markedly improved the renal function, relieve inflammation, reversed inflammatory cytokines, transformed apoptosis markers, and regulated the TLR4 signaling pathway in mice with AKI induced by LPS. The protopine isolated from C. humosa Migo protected mice against LPS-induced AKI by inhibiting apoptosis and inflammation via the TLR4 signaling pathway, thus providing a molecular basis for a novel medical treatment of AKI.


2019 ◽  
Vol 4 (7) ◽  
pp. S50-S51
Author(s):  
T. INOUE ◽  
J. Yao ◽  
L. Huang ◽  
D. Rosin ◽  
K. Ishihara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document